Annual Cash & Cash Equivalents
$51.35 M
-$35.17 M-40.65%
31 December 2023
Summary:
ADMA Biologics annual cash & cash equivalents is currently $51.35 million, with the most recent change of -$35.17 million (-40.65%) on 31 December 2023. During the last 3 years, it has fallen by -$4.57 million (-8.17%). ADMA annual cash & cash equivalents is now -40.65% below its all-time high of $86.52 million, reached on 31 December 2022.ADMA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$86.71 M
-$1.54 M-1.74%
30 September 2024
Summary:
ADMA Biologics quarterly cash and cash equivalents is currently $86.71 million, with the most recent change of -$1.54 million (-1.74%) on 30 September 2024. Over the past year, it has increased by +$12.55 million (+16.92%). ADMA quarterly cash and cash equivalents is now -14.35% below its all-time high of $101.24 million, reached on 31 March 2020.ADMA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADMA Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -40.6% | +16.9% |
| 3 y3 years | -8.2% | +152.0% |
| 5 y5 years | +125.7% | +80.6% |
ADMA Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -40.6% | +0.5% | -1.7% | +152.0% |
| 5 y | 5 years | -40.6% | +125.7% | -14.3% | +224.1% |
| alltime | all time | -40.6% | >+9999.0% | -14.3% | >+9999.0% |
ADMA Biologics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $86.71 M(-1.7%) |
| June 2024 | - | $88.24 M(+94.7%) |
| Mar 2024 | - | $45.33 M(-11.7%) |
| Dec 2023 | $51.35 M(-40.6%) | $51.35 M(-30.8%) |
| Sept 2023 | - | $74.16 M(+18.6%) |
| June 2023 | - | $62.51 M(-9.7%) |
| Mar 2023 | - | $69.20 M(-20.0%) |
| Dec 2022 | $86.52 M(+69.4%) | $86.52 M(+147.9%) |
| Sept 2022 | - | $34.91 M(-33.4%) |
| June 2022 | - | $52.42 M(-24.6%) |
| Mar 2022 | - | $69.50 M(+36.0%) |
| Dec 2021 | $51.09 M(-8.6%) | $51.09 M(+48.5%) |
| Sept 2021 | - | $34.41 M(-18.9%) |
| June 2021 | - | $42.41 M(-31.6%) |
| Mar 2021 | - | $61.97 M(+10.8%) |
| Dec 2020 | $55.92 M(+109.0%) | $55.92 M(-6.3%) |
| Sept 2020 | - | $59.67 M(-21.3%) |
| June 2020 | - | $75.78 M(-25.1%) |
| Mar 2020 | - | $101.24 M(+278.4%) |
| Dec 2019 | $26.75 M(+17.6%) | $26.75 M(-44.3%) |
| Sept 2019 | - | $48.01 M(-34.8%) |
| June 2019 | - | $73.62 M(+345.2%) |
| Mar 2019 | - | $16.53 M(-27.3%) |
| Dec 2018 | $22.75 M(-47.2%) | $22.75 M(-46.3%) |
| Sept 2018 | - | $42.37 M(-23.2%) |
| June 2018 | - | $55.15 M(+111.2%) |
| Mar 2018 | - | $26.12 M(-39.4%) |
| Dec 2017 | $43.11 M | $43.11 M(+216.9%) |
| Sept 2017 | - | $13.60 M(-46.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2017 | - | $25.57 M(+199.4%) |
| Mar 2017 | - | $8.54 M(-13.8%) |
| Dec 2016 | $9.91 M(-5.0%) | $9.91 M(+25.4%) |
| Sept 2016 | - | $7.91 M(-37.0%) |
| June 2016 | - | $12.55 M(+40.6%) |
| Mar 2016 | - | $8.93 M(-14.5%) |
| Dec 2015 | $10.44 M(-39.3%) | $10.44 M(+13.8%) |
| Sept 2015 | - | $9.18 M(+17.3%) |
| June 2015 | - | $7.82 M(-52.8%) |
| Mar 2015 | - | $16.56 M(-3.7%) |
| Dec 2014 | $17.20 M(-34.2%) | $17.20 M(+23.3%) |
| Sept 2014 | - | $13.95 M(-21.9%) |
| June 2014 | - | $17.87 M(-32.6%) |
| Mar 2014 | - | $26.52 M(+1.4%) |
| Dec 2013 | $26.15 M(+108.6%) | $26.15 M(+386.1%) |
| Sept 2013 | - | $5.38 M(-29.7%) |
| June 2013 | - | $7.65 M(-25.8%) |
| Mar 2013 | - | $10.32 M(-17.7%) |
| Dec 2012 | $12.54 M(>+9900.0%) | $12.54 M(+16.9%) |
| Sept 2012 | - | $10.72 M(-16.8%) |
| June 2012 | - | $12.89 M(-9.5%) |
| Mar 2012 | - | $14.24 M(>+9900.0%) |
| Dec 2011 | - | $8100.00(+37.3%) |
| Sept 2011 | - | $5900.00(-30.6%) |
| June 2011 | $8500.00(-29.2%) | $8500.00(-47.5%) |
| Mar 2011 | - | $16.20 K(+422.6%) |
| Dec 2010 | - | $3100.00(-74.2%) |
| June 2010 | - | $12.00 K |
| June 2010 | $12.00 K | - |
FAQ
- What is ADMA Biologics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ADMA Biologics?
- What is ADMA Biologics annual cash & cash equivalents year-on-year change?
- What is ADMA Biologics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ADMA Biologics?
- What is ADMA Biologics quarterly cash and cash equivalents year-on-year change?
What is ADMA Biologics annual cash & cash equivalents?
The current annual cash & cash equivalents of ADMA is $51.35 M
What is the all time high annual cash & cash equivalents for ADMA Biologics?
ADMA Biologics all-time high annual cash & cash equivalents is $86.52 M
What is ADMA Biologics annual cash & cash equivalents year-on-year change?
Over the past year, ADMA annual cash & cash equivalents has changed by -$35.17 M (-40.65%)
What is ADMA Biologics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ADMA is $86.71 M
What is the all time high quarterly cash and cash equivalents for ADMA Biologics?
ADMA Biologics all-time high quarterly cash and cash equivalents is $101.24 M
What is ADMA Biologics quarterly cash and cash equivalents year-on-year change?
Over the past year, ADMA quarterly cash and cash equivalents has changed by +$12.55 M (+16.92%)